Meeting NewsVideo

Early steroid use may reduce CAR T-cell treatment-related toxicity in aggressive lymphoma

ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response rates in patients with relapsed/refractory large B-cell lymphoma who received CAR T-cell treatment, according to study results presented in a video at ASH Annual Meeting and Exposition.

In their study, Max Topp, MD, of the University Hospital Würzburg in Germany, and colleagues introduced a revised risk-benefit management profile adding earlier steroid use to mitigate cytokine release syndrome and neurotoxicity. They found reduced cytokine levels in patients who received steroids and that the expansion of the CAR T-cells was not impacted by earlier steroid use.

“The most important fact is that this didn’t have any impact on the overall response rate as well on the long-term disease control for those patients being treated with early steroids onward,” he said. “Altogether, I believe that with this new risk-benefit management profile we have a means of actually delivering the CAR T-cells more effectively to the patients with less toxicity.”

Disclosures: Topp reports research funding from Amgen, Kite, Regeneron and Roche; consulting for Amgen, Kite, Novartis, Regeneron, Roche; honoraria from Amgen, being on the speakers bureau for Prime; and travel support from Amgen, Celgene and Gilead.

 

ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response rates in patients with relapsed/refractory large B-cell lymphoma who received CAR T-cell treatment, according to study results presented in a video at ASH Annual Meeting and Exposition.

In their study, Max Topp, MD, of the University Hospital Würzburg in Germany, and colleagues introduced a revised risk-benefit management profile adding earlier steroid use to mitigate cytokine release syndrome and neurotoxicity. They found reduced cytokine levels in patients who received steroids and that the expansion of the CAR T-cells was not impacted by earlier steroid use.

“The most important fact is that this didn’t have any impact on the overall response rate as well on the long-term disease control for those patients being treated with early steroids onward,” he said. “Altogether, I believe that with this new risk-benefit management profile we have a means of actually delivering the CAR T-cells more effectively to the patients with less toxicity.”

Disclosures: Topp reports research funding from Amgen, Kite, Regeneron and Roche; consulting for Amgen, Kite, Novartis, Regeneron, Roche; honoraria from Amgen, being on the speakers bureau for Prime; and travel support from Amgen, Celgene and Gilead.

 

    See more from Discoveries from ASH: Lymphoma